Savvy Psychopharmacology
Savvy Psychopharmacology
Mood stabilizers: Balancing tolerability, serum levels, and dosage
Mr. B, age 32, was diagnosed with bipolar disorder 10 years ago after experiencing a manic episode that resulted in his first psychiatric...
Savvy Psychopharmacology
Efficacy and safety of high-dose antipsychotic therapy
Mr. K, age 21, is admitted to the psychiatry unit with agitation, disorganized behavior, and paranoia. Upon presentation, he has no known medical...
Savvy Psychopharmacology
Prazosin for PTSD: Sorting out the evidence
Mr. H, age 43, presents to your clinic for management of posttraumatic stress disorder (PTSD).
Savvy Psychopharmacology
Antidepressants: Is a higher dose always better?
Mr. E, age 39, presents to the mental health (MH) intake clinic, reporting he has had depressed mood almost every day, lack of interests, poor...
Savvy Psychopharmacology
Management of major depressive disorder with psychotic features
Mrs. C, age 56, has a history of major depressive disorder (MDD).
Savvy Psychopharmacology
Pharmacotherapy for alcohol use disorder in patients with hepatic impairment
The risk of alcoholic liver disease increases with daily alcohol consumption; however, it is also dependent on genetic predisposition, age, gender...
Savvy Psychopharmacology
Impact of the MTHFR C677T genetic variant on depression
Data suggesting that the C677T mutation in MTHFR may be associated with depression have been inconsistent.
Savvy Psychopharmacology
CYP450 interactions between illicit substances and prescription medications
Many illicit substances are metabolized to some degree by CYP450 enzymes, increasing the risk for drug–drug interactions when illicit substances...
Savvy Psychopharmacology
Polypharmacy in older adults
Mrs. B, age 66, presents to the emergency department with altered mental status, impaired gait, and tremors.
Savvy Psychopharmacology
Therapeutic drug monitoring of antipsychotics
Mr. Q, age 36, has a history of schizophrenia. He is brought to the hospital due to persistent auditory hallucinations and paranoid delusions.
Savvy Psychopharmacology
Valproic acid-induced hyperammonemic encephalopathy
Hyperammonemia can occur in individuals receiving VPA and is most often asymptomatic.